AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03539575 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: [11-C]OMAR
Description: The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
Study NCT01341028 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y gastric bypass (LRYGBP)
Description: Twelve patients underwent laparoscopic Roux-en-Y gastric bypass
Study NCT01341028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LRYGBP+gastric fundus resection
Description: Twelve patients underwent laparoscopic Roux-en-Y gastric bypass and gastric fundus resection
Study NCT02328027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-rhAnnexin V-128
Description: 1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.
Study NCT01189591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slow-wave deprivation
Description: Using acoustic tones to suppress slow-wave sleep
Study NCT01736618 — intervention group
Intervention type: DEVICE
Intervention: S-ICD System
Study NCT01507480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: There are five increasing doses of bevacizumab nasal spray (25mg/mL): 10 mg, 25 mg, 50 mg, 75, mg and 100 mg. Each test dose is a single dose divided into five fractions and administered into each nostril every 30 minutes for 2 hours:
Study NCT00819117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy implant
Description: Device implant with appropriate leads
Study NCT00819117 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy implant
Description: Device implant with appropriate leads
Study NCT02861599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprioceptive therapy
Study NCT02861599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speech therapy
Study NCT02861599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: speech therapy
Study NCT00731471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.
Study NCT02576951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study NCT02576951 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03466528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Intravenous (Magnesium Sulphate) MgSO4 2 grams IV over 20 minutes
Study NCT03466528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Intravenous (Magnesium Sulphate) MgSO4 2 grams IV over 20 minutes
Study NCT03466528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pabrinex
Description: standard treatment
Study NCT01790451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irreversible Electroporation
Study NCT03104361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
Study NCT02010489 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 12 week Exercise Program
Description: Patients will be provided with a tour of the Reh-Fit Centre, exercise prescription, and supervised exercise session. The exercise prescription consists of 3 weekly 60-minute sessions, each with 10 minutes warm-up, 30 minutes endurance, 20 minutes strength training and 5 minutes cool-down. The program is overseen by an accredited Exercise Physiologist. Initial exercise intensity is determined by the kinesiologist and based on the patient's baseline fitness level. Goal intensity of endurance activity is based on the heart rate reserve (HRR) method. This is captured with a heart rate monitor at initial assessment and recorded on exercise logs. There are check-ins at each exercise session to determine progress (time, reps, weight, sets, etc). Endurance activities include treadmill, elliptical, walking, and aerobics. Strength training includes upper body, lower body, and trunk circuits. Patients will be asked to attend three weekly sessions at the Reh-Fit Centre.
Study NCT02145715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Study NCT01505608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
Study NCT01505608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle
Study NCT01505608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle
Study NCT01748825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1775 (AZD1775)
Description: MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.
Study NCT01505608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
Study NCT00002704 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00002704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Study NCT00002704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00002704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Study NCT00002704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00002704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT02160691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anxiety Meter
Description: This is a new device developed to measure changes in heart rate and translate these into a visual display of arousal level in children with autism spectrum disorder.
Study NCT03951558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet for calciuria prevention
Description: Dietary recommendations for water, salt, calcium and proteins according to age and DIR
Study NCT03951558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydroclorothiazide recommendations for hypercalciuria
Study NCT03903887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-PD1 antibody-activated TILs
Description: Participants would receive one dose of anti-PD1 antibody-activated TILs at the final cycle of docetaxel and cisplatin (DP) regimen chemotherapy.
Study NCT02567994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teneligliptin
Description: Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
Study NCT02567994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin
Description: Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
Study NCT03181776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: left lateral tilting in 15 degrees
Description: The mother will be placed in left lateral tilted position (15 degrees) using a standard wedge
Study NCT03181776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: left lateral tilting in 30 degrees
Description: The mother will be placed in left lateral tilted position (30 degrees) using a standard wedge
Study NCT03181776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supine position
Description: The mother will be placed in standard supine position
Study NCT01952041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Device: Smartphone
Study NCT01952041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Study NCT02138864 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FP-(+)-DTBZ
Description: no available
Study NCT03826641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1805
Description: Dapagliflozin/Metformin (Xigduo XR) 10/1000mg
Study NCT03826641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1801
Description: Dapagliflozin/Metformin 10/1000mg
Study NCT03570476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given orally
Study NCT03570476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo surgery
Study NCT04917666 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horticultural therapy
Description: A structured 8-session group therapy program, in which participants learn about plants, green spaces, plant-human interactions. During the program, the participants are guided by therapist to grow or take care of both indoor and outdoor plants, do small horticulture projects (like cooking, making drinks, herb projects).
Study NCT04917666 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparison
Description: 4 session of semi-structured and free engagement in activities of their choice. The activities that they could choose are mostly table-top activities which are solitary in nature, and does not require social interaction.
Study NCT04076865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA (lidocaine) +Itch (Histamine and cowhage)
Description: Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).~Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.~Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain.
Study NCT03674645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI acquisitions
Description: Procedure of the study is an MRI exam without any injection or invasive procedure, that will be performed on the Siemens Magnetom Aera imager of Liryc institute (L'Institut de RYthmologie et modélisation Cardiaque) (Xavier Arnozan site - Bordeaux)
Study NCT02651311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermediate cervical plexus block
Description: ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg
Study NCT02651311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
Study NCT02651311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
Study NCT02651311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: ibuprofen in ward when more or equal to FLACC scale 4.
Study NCT02651311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: ibuprofen in ward when more or equal to FLACC scale 4.
Study NCT01143662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b
Description: sc, qw, for 48 weeks.
Study NCT01143662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: sc, qw, for 48 weeks.
Study NCT03968263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Routine protocol)
Description: Hycon device will be activated half a turn every 3 days.
Study NCT03968263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Modified protocol)
Description: The activation period of the hycon device will be modified.
Study NCT03968263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Routine protocol) and Vibration(Acceledent)
Description: Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.
Study NCT00002704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT01505608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
Study NCT03968263 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hycon device(Modified protocol) and Vibration(Acceledent)
Description: The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.
Study NCT00002704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal cytarabine
Study NCT01311440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins diet treatment
Description: Eat a diet containing 16 grams of carbohydrates per day, maximize on fat. Assure sufficient intake of micronutrients.
Study NCT03882645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHH-diet
Description: This study took the DASH Diet as the basic model and developed the Chinese Heart Healthy Diet ( CHH-diet) according to the principles in the 2016 Dietary Guidelines for Chinese Residents. The nutrients targets in CHH-diet are set as following: fat % of total kcal: 25-27% (saturated: 6%; monounsaturated: 12%; polyunsaturated: 8%); carbohydrate % of total kcal: 55-60%; protein % of total kcal: 17-19%; dietary fiber: 30 g/day; sodium: 3000 mg/day; potassium: 3700 mg/day; magnesium: 500 mg/day; calcium: 1200 mg/day. The total energy will be set according to how much participants are eating in run-in period.
Study NCT03882645 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: local usual diet
Description: The nutrients targets and total energy in usual diet are set according to how much participants are eating in run-in period.
Study NCT04266236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L3 LPB
Description: ultrasound-guided L3 lumbar plexus block
Study NCT04266236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L3 LPB
Description: ultrasound-guided L3 lumbar plexus block
Study NCT04266236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L4 LPB
Description: ultrasound-guided L4 lumbar plexus block
Study NCT04266236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T12 block
Description: ultrasound-guided thoracic 12th segment nerve block
Study NCT04266236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L3 QLB
Description: ultrasound-guided quadratus lumborum block at L3 level
Study NCT04266236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.375%ropivacaine 25 ml (Raropin)
Description: 0.375%ropivacaine (Raropin) 25ml will be given
Study NCT04266236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.375%ropivacaine 40 ml (Raropin)
Description: 0.375%ropivacaine (Raropin) 40ml will be given
Study NCT04266236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.375%ropivacaine 40 ml (Raropin)
Description: 0.375%ropivacaine (Raropin) 40ml will be given
Study NCT04266236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia with tracheal intubation
Description: General anesthesia with tracheal intubation will be induced with sufentanil, propofol, vecuronium for every patient before the operation and maintained with sevoflurane during the operation
Study NCT04266236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with tracheal intubation
Description: General anesthesia with tracheal intubation will be induced with sufentanil, propofol, vecuronium for every patient before the operation and maintained with sevoflurane during the operation
Study NCT02607111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Study NCT01962272 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly nutritional counseling
Description: The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.
Study NCT01180673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINT-TLC
Description: This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension, which recommend weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. Seniors will attend weekly group classes conducted by trained research assistants for the first 12 weeks (intensive phase); followed by three individual motivational interview (MINT) sessions that will occur monthly over the next three months (extended phase); and finally each senior will receive three bi-monthly booster MINT sessions in the remaining six months (maintenance phase).
Study NCT01180673 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: Seniors randomized to the control arm will receive a single individual brief advice session on therapeutic lifestyle changes recommended for blood pressure reduction. In addition, they will be given print versions of the NHLBI publications Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan. Sessions will be delivered by trained research assistants.
Study NCT04483713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Workshop
Description: The workshop proposes a review of all stages of EBP which includes approaches to clinical care based on science and the quality of evidence, with the ultimate goal of promoting safe and quality care.~The workshops comprise one for each group with a total workload of six (6) hours divided into two days, lasting three hours each day. The first day will be a theoretical approach and the second day a practical approach.~The workshops with theoretical content and practical classes will be held in rooms of Albert Einstein Hospital.~All participants of both educational strategies will answer the same questionnaires.
Study NCT03253328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Arm N-acetyl cysteine (NAC)
Description: N-acetyl cysteine (NAC) 1200mg twice a day for 6 days post-amputation
Study NCT03253328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: Placebo 1/2 normal saline infusion twice a day for 6 days post-amputation
Study NCT02772627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebicapone
Description: Nebicapone 100 mg tablets; oral route.
Study NCT02772627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets; oral route.
Study NCT01467830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures
Description: use of absorbable sutures to fixate mesh inguinal hernia repair.
Study NCT00002704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Study NCT01467830 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures
Description: use of absorbable sutures to fixate mesh inguinal hernia repair.
Study NCT00317382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound used to visualize spine to determine best location for lumbar puncture.
Study NCT04937283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmentectomy with systemic lymph node dissection
Description: Segmentectomy with hilar and mediastinal lymph node dissection is performed. If the tumor located at inter-segment plane and without sufficient resection margin distance, a combined segmentectomy will be performed. Systemic or selective lymph node dissection is mandatory, and nodal sampling is not allowed. At least three stations of mediastinal lymph node from 2R, 4R, 7, 8, 9 for the right side and 5, 6, 7, 8, 9 for the left side, respectively. The distance from the dissection margin to the tumor edge must be evaluated intra-operatively. If the distance is either less than the maximum tumor diameter or 20 mm, the absence of cancer cells in the resection margin must be histologically or cytologically confirmed before finishing surgery.